Telix Pharmaceuticals
Logotype for Telix Pharmaceuticals Limited

Telix Pharmaceuticals (TLX) investor relations material

Telix Pharmaceuticals Bell Potter Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Telix Pharmaceuticals Limited
Bell Potter Healthcare Conference summary17 Nov, 2026

Commercial platform and outlook

  • Three FDA-approved precision medicine products serve prostate and brain cancer; commercial sales span 22 countries, supported by 45 manufacturing sites globally.

  • 2026 revenue expected just under US$1 billion, with guidance projected at the top end; precision medicine revenue is expected to grow more than 25% YoY.

  • Radiopharma growth drivers targeted for 2027 include Illuccix and Gozellix, new products and indications, expansion into China and Japan, Telix Manufacturing Solutions revenue, and ITM assets.

  • ITM acquisition is intended to secure lutetium supply and add complementary pipeline assets; settlement is due early in 2027.

BiPASS prostate study

  • Phase III BiPASS compares gallium PSMA PET plus MRI with MRI alone for detecting clinically significant prostate cancer; 350 patients enrolled at U.S. and Australian sites, with enrollment completed in June.

  • The trial builds on PRIMARY2 findings that PSMA PET could help roughly half of patients avoid biopsy without missing clinically significant cancer; its FDA-negotiated design is intended to generate submission-ready data.

  • Six-month follow-up puts study data due around Q1 2027; a new drug application is planned for Q2 2027, following granted fast-track designation.

  • Starting in 2027, PSMA PET plus MRI is expected to support biopsy avoidance for suitable patients and more targeted biopsies for others.

Pixclara and brain imaging

  • FDA approved Pixclara, a FET PET imaging agent, in September for assessing suspected recurrent glioma after initial treatment; commercial use has begun.

  • Pixclara currently uses a not-otherwise-classified reimbursement code; a temporary pass-through code is expected in Q1 2027, when broader commercial scale-up is anticipated.

  • A Phase III trial is about to start to pursue a brain-metastases indication, a market described as about 10 times the size of primary brain cancer.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Telix Pharmaceuticals earnings date

Logotype for Telix Pharmaceuticals Limited
AGM 202630 Nov, 2026
Telix Pharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Telix Pharmaceuticals earnings date

Logotype for Telix Pharmaceuticals Limited
AGM 202630 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Telix Pharmaceuticals Limited is a global biopharmaceutical company at the commercial stage, primarily engaged in developing diagnostic and therapeutic products using targeted radiation for cancer and rare diseases. The company is pioneering in the field of radiopharmaceuticals, aiming to advance precision medicine through its innovative approach. Telix's product development focuses on molecularly targeted radiation (MTR) products that seek to improve patient outcomes by precisely targeting diseased cells, thereby minimizing the impact on healthy tissues. Its research pipeline includes a range of diagnostic and therapeutic agents for conditions such as prostate cancer, kidney cancer, glioblastoma (brain cancer), and hematologic cancers, as well as bone marrow conditioning for rare diseases. TThe company is headquartered in North Melbourne, Australia, and its shares are listed on the ASX.